Biogen operates several manufacturing facilities around the world. Together, they total 198,000 liters of bioreactor capacity, one of the largest among biotech companies worldwide.

Research Triangle Park (RTP), North Carolina

  • Produces:
  • AVONEX® (interferon beta-1a)
  • PLEGRIDY® (peginterferon beta-1a)
  • TECFIDERA® (dimethyl fumerate)
  • TYSABRI® (natalizumab) (for U.S. only)
  • ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein]*
  • ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein]*

In 2013, RTP won the Facility of the Year award in the facility integration category from the International Society for Pharmaceutical Engineering, Pharmaceutical Processing magazine and INTERPHEX, one of the industry’s leading trade events. With this facility we introduced an innovative process for early-stage clinical products. Single-use technology in a closed system replaces the traditional stainless-steel systems. This increases flexibility and speed of supplying drugs for clinical studies, and reduces the environmental impacts of the manufacturing process.

Hillerød, Denmark

Large-scale manufacturing

  • Produces:
  • TYSABRI® (natalizumab) (for outside of the U.S.)
  • Clinical products
  • Medical device assembly:
  • AVONEX® Pen (interferon beta-1a)
  • PLEGRIDY® Pen (peginterferon beta-1a)
  • Labeling and packing (for outside the U.S.):
  • AVONEX® (interferon beta-1a)
  • TYSABRI® (natalizumab)
  • ALPROLIX® [Coagulation Factor IX (Recombinant), Fx Fusion Protein]*
  • ELOCTATE® [Antihemophilic Factor
    (Recombinant), Fc Fusion Protein]*

Biogen’s Hillerød campus brings together a complete range of expertise, capabilities and technologies to reliably manufacture advanced biologics. Our large-scale manufacturing facility manufactures innovative therapies and biosimilars for clinical and commercial use. Our medical device assembly, labeling and packing prepares medicines for delivery to more than 90 countries. The campus is the single-largest foreign greenfield investment in Denmark.

Solothurn, Switzerland

Construction on this next-generation biologics manufacturing facility began in 2016 and is expected to be completed in 2019. The Solothurn facility will produce up to ten metric tons of antibody per year, helping us provide meaningful therapies to patients with serious medical conditions around the globe.

View Solothurn Manufacturing Careers

*Biogen will continue to manufacture ALPROLIX and ELOCTATE following the Bioverativ spin-off.